Peniskrebs: Unterschied zwischen den Versionen

K using Template:PhD
K REFjournal uses <init> key
 
Zeile 115: Zeile 115:
In Japan, Norway, and Sweden, the risk of penile cancer is about the same  as in the US (1 in 100,000 per year).<ref>{{REFjournal
In Japan, Norway, and Sweden, the risk of penile cancer is about the same  as in the US (1 in 100,000 per year).<ref>{{REFjournal
  |last=Wallerstein
  |last=Wallerstein
  |first=E.
  |init=E
|author-link=Edward Wallerstein
  |title=Circumcision. The uniquely American medical enigma
  |title=Circumcision. The uniquely American medical enigma
  |journal=Urol. Clin. North Am.
  |journal=Urol Clin North Am
  |volume=12
  |volume=12
  |issue=1
  |issue=1
Zeile 135: Zeile 136:


Infection with HPV is associated with some penile cancers.  A quadri-valent vaccine ([[Gardasil]]) to prevent infection by the four most common variants of HPV has been developed, successfully tested, and approved by the US [[Food and Drug Administration]] for females between the ages of 9 and 26, and as of 2009, males between the ages of 16 and 26.<ref name="titleAccess to articles : Nature Reviews Drug Discovery">{{REFjournal
Infection with HPV is associated with some penile cancers.  A quadri-valent vaccine ([[Gardasil]]) to prevent infection by the four most common variants of HPV has been developed, successfully tested, and approved by the US [[Food and Drug Administration]] for females between the ages of 9 and 26, and as of 2009, males between the ages of 16 and 26.<ref name="titleAccess to articles : Nature Reviews Drug Discovery">{{REFjournal
  |last=Crum C, Jones C, Kirkpatrick P
  |last=Crum
  |first=
|init=C
|last2=Jones
|init2=C
|last3=Kirkpatrick
  |init3=P
  |title=Quadrivalent human papillomavirus recombinant vaccine
  |title=Quadrivalent human papillomavirus recombinant vaccine
  |journal=Nature reviews. Drug discovery
  |journal=Nature reviews. Drug discovery